8-K: Seer Inc. Reports Second Quarter 2024 Financial Results, Launches STAC in Europe

Seer Inc. announced its second quarter 2024 financial results, including a revenue of $3.1 million and the launch of its Seer Technology Access Center (STAC) in Europe.

Summary

• Seer Inc. reported a revenue of $3.1 million for the second quarter of 2024, which is a 23% decrease compared to the $4.0 million reported in the same period last year.
• The decrease in revenue was primarily due to a reduction in related party and grant revenue.
• Product revenue was $2.2 million, including $420 thousand from related parties, and service revenue was $845 thousand, including $163 thousand from related parties.
• The company's gross profit was $1.7 million with a gross margin of 56%.
• Operating expenses decreased by 5% to $28.8 million, driven by lower employee and stock-based compensation and laboratory expenses.
• Net loss for the quarter was $22.9 million, slightly better than the $23.4 million loss in the same quarter of the previous year.
• Seer ended the quarter with $344.6 million in cash, cash equivalents, and investments.
• The company has revised its full-year 2024 revenue guidance to a range of $13 million to $15 million, down from the previous range of $16 million to $18 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive aspects like the launch of STAC in Europe and strong cash reserves, the significant revenue decrease and lowered guidance are concerning. The company is still in a growth phase, but the financial results indicate challenges.

Positives

• The launch of the STAC in Europe expands access to Seer's technology.
• Customer publications in high-impact journals validate the capabilities of the Proteograph Product Suite.
• The company maintains a strong cash position with $344.6 million in cash, cash equivalents, and investments.
• Operating expenses decreased by 5% year-over-year, indicating improved cost management.
• The net loss improved slightly compared to the same quarter last year.

Negatives

• Revenue decreased by 23% year-over-year, primarily due to a decrease in related party and grant revenue.
• The company has lowered its full-year 2024 revenue guidance from $16-$18 million to $13-$15 million.
• The company reported a net loss of $22.9 million for the quarter.

Risks

• The company faces ongoing macroeconomic headwinds that may impact its ability to reduce barriers to access for its technology.
• The decrease in related party and grant revenue poses a risk to future revenue growth.
• The company's reliance on customer publications to drive adoption may be affected by the pace of scientific research.
• The company's revised revenue guidance indicates potential challenges in achieving its initial financial targets.

Future Outlook

Seer expects full-year 2024 revenue to be in the range of $13 million to $15 million. The company will continue to focus on driving evidence and publications, enhancing access to the Proteograph, innovating with products, and expanding applications.

Management Comments

• Omid Farokhzad, Chair and CEO of Seer, stated that the company is focused on reducing barriers to access for its technology.
• Omid Farokhzad also mentioned that the company significantly expanded its commercial team during the second quarter.
• Management believes that customers are generating novel data only possible with the Proteograph Product Suite.

Industry Context

The announcement reflects the ongoing challenges and opportunities in the life sciences sector, particularly in the proteomics field. The launch of STAC in Europe indicates a strategic move to expand market reach and adoption of Seer's technology. The company's focus on publications and evidence generation aligns with the industry's emphasis on scientific validation.

Comparison to Industry Standards

• Seer's revenue of $3.1 million is relatively low compared to established proteomics companies like Thermo Fisher Scientific or Danaher, which report billions in quarterly revenue.
• The 23% year-over-year revenue decrease is concerning, as many biotech companies in the growth phase aim for significant revenue increases.
• The gross margin of 56% is within the typical range for life science companies, but the company needs to scale revenue to achieve profitability.
• Seer's cash position of $344.6 million is strong compared to many early-stage biotech companies, providing a runway for further development and commercialization.
• The company's focus on publications in high-impact journals is a positive sign, as it demonstrates the scientific validity of its technology, similar to companies like 10x Genomics that rely on peer-reviewed publications to drive adoption.

Related Party Transactions

• Related party revenue was $420 thousand in product revenue and $163 thousand in service revenue for the second quarter of 2024.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and lowered guidance.
• Employees may be affected by the company's cost-cutting measures.
• Customers may benefit from the expanded access to Seer's technology through the STAC program.
• Suppliers may be impacted by changes in the company's spending.

Next Steps

• Seer will continue to execute against its core strategies of driving evidence and publications.
• The company will continue to enhance access to the Proteograph.
• Seer will continue to innovate with its products.
• The company will continue to expand its applications.

Key Dates

Keywords

proteomics, life sciences, Seer, Proteograph, STAC, revenue, financial results, biotechnology, research, nanoparticles